QQ客服 官方微博 反馈留言

	Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
	Zhang, Jingjing; Wang, Hao; Jacobson, Orit; Cheng, Yuejuan; Niu, Gang; Li, Fang; Bai, Chunmei; Zhu, Zhaohui; Chen, Xiaoyuan
	2018
卷号	59期号:11页码:1699-1705
关键词	peptide receptor radionuclide therapy (PRRT) somatostatin receptor (SSTR) neuroendocrine tumor (NET) Evans blue TATE
ISSN号	0161-5505
DOI	10.2967/jnumed.118.209841
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6360336
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Zhang, Jingjing,Wang, Hao,Jacobson, Orit,et al. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors[J],2018,59(11):1699-1705.
APA	Zhang, Jingjing.,Wang, Hao.,Jacobson, Orit.,Cheng, Yuejuan.,Niu, Gang.,...&Chen, Xiaoyuan.(2018).Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.,59(11),1699-1705.
MLA	Zhang, Jingjing,et al."Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Lu-177-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors".59.11(2018):1699-1705.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。